Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus Vaccines
New hepatitis C virus vaccines research from E. Fenouillet et al outlined
October 29th, 2008
Fresh data on hepatitis C virus are presented in the report 'Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.' According to a study from France, "Disulfide bonding contributes to the function and antigenicity of many viral envelope glycoproteins. We assessed here its significance for the hepatitis C virus E2 envelope protein and a counterpart deleted for hypervariable region-1 (HVR1)." "All 18 cysteine residues of the antigens were involved in disulfides. Chemical reduction of up to half of these disulfides was compatible with anti-E2 monoclonal antibody reaction, CD81 receptor binding, and viral entry, whereas complete...
Source: Vaccine Weekly (2008-10-29)
|
